{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/optimizing-phase-ib-right-partner#webpage",
"url": "https://www.fortrea.com/insights/optimizing-phase-ib-right-partner",
"name": "Optimizing Phase Ib with the right partner",
"description": "This Fortrea infosheet explores the operational and scientific considerations involved in Phase Ib clinical trials and early oncology development programs. The content focuses on challenges associated with dose escalation strategies, biomarker integration, patient safety monitoring, and complex clinical trial operations during early-phase oncology research. The infosheet highlights how Phase Ib clinical trials increasingly require integrated planning across translational science, clinical operations, safety oversight, and biomarker-driven development to support informed early development decision-making. Fortrea outlines capabilities designed to support oncology sponsors through early clinical development activities that involve adaptive trial execution, patient monitoring, operational coordination, and evolving therapeutic strategies within complex oncology environments. By integrating scientific expertise with early-phase operational support and clinical development strategy, the infosheet provides insights into managing Phase Ib oncology trials and advancing early clinical development programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Optimizing Phase Ib with the right partner",
"item": "https://www.fortrea.com/insights/optimizing-phase-ib-right-partner"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/optimizing-phase-ib-right-partner#infosheet",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/optimizing-phase-ib-right-partner#webpage"
},
"headline": "Choosing the Right Partner for Phase Ib Clinical Trials and Early Oncology Development | Fortrea Infosheet",
"description": "This Fortrea infosheet explores the operational and scientific considerations involved in Phase Ib clinical trials and early oncology development programs. The content focuses on challenges associated with dose escalation strategies, biomarker integration, patient safety monitoring, and complex clinical trial operations during early-phase oncology research. The infosheet highlights how Phase Ib clinical trials increasingly require integrated planning across translational science, clinical operations, safety oversight, and biomarker-driven development to support informed early development decision-making. Fortrea outlines capabilities designed to support oncology sponsors through early clinical development activities that involve adaptive trial execution, patient monitoring, operational coordination, and evolving therapeutic strategies within complex oncology environments. By integrating scientific expertise with early-phase operational support and clinical development strategy, the infosheet provides insights into managing Phase Ib oncology trials and advancing early clinical development programs.",
"genre": "Info Sheet",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-11-26",
"dateModified": "2025-11-26",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/insights/optimizing-phase-ib-right-partner",
"encodingFormat": "application/pdf"
}
}
]
}